Compare PHVS & KSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHVS | KSS |
|---|---|---|
| Founded | 2015 | 1962 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2020 | 1995 |
| Metric | PHVS | KSS |
|---|---|---|
| Price | $37.87 | $16.39 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 11 | 15 |
| Target Price | ★ $41.82 | $15.31 |
| AVG Volume (30 Days) | 1.0M | ★ 4.0M |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 3.58% |
| EPS Growth | N/A | ★ 142.86 |
| EPS | N/A | ★ 1.18 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.21 |
| P/E Ratio | ★ N/A | $14.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.65 | $11.38 |
| 52 Week High | $43.25 | $25.22 |
| Indicator | PHVS | KSS |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 39.67 |
| Support Level | $24.95 | $16.19 |
| Resistance Level | $43.25 | $20.00 |
| Average True Range (ATR) | 2.09 | 1.05 |
| MACD | 0.20 | -0.20 |
| Stochastic Oscillator | 45.08 | 17.42 |
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.